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Received January 27, 2011; accepted May 24, 2011AbstractBackground: Increasing reported cases with Chrombacterium violaceum infection has been noticed in recent decades. It is noteworthy for its
difficult-to-treat entity characterized by a high frequency of sepsis, easily distantant metastasis, multidrug-resistance, and frequent relapse, and
high mortality rate.
Methods: The English-language literature was reviewed from 1952 through December 2009 by an electronic view via the PubMed and Medline
databases and manual searches.
Results: One hundred and six patients with Chrombacterium violaceum infection from the literature were studied. The four leading clinical
manifestations reviewed in the published literature, in the order of frequency, were fever (100%), sepsis (82%), skin lesions (67.9%), and
abdominal pain (31.1%). Localized abscess was found in 52 patients (49%) and liver was the mostly common involved organ. Fifty-six patients
(53%) were dead. Almost all of the penicillin, ampicillin, and first and second-generation cephalosporins exhibited totally resistant to
Chrombacterium violaceum. The most important risk factors in mortality in 61 patients with Chrombacterium violaceum bacteremia were at
a young age (p ¼ 0.0789), presence of localized abscess (p ¼ 0.030), shorter clinical course (p < 0.001), and inappropriate antimicrobial
treatment (p < 0.001). Seven patients (6.6%) experienced of relapse or reinfection, with a median interval of 135 days (range, 4 to 1095 days).
Conclusions: A high index of suspicion for Chromobacterium violaceum infection is required along with prompt diagnosis, optimal antimi-
crobial therapy, and adequate therapeutic duration for a successful therapy.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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11. Introduction
Chromobacterium violaceum is a gram-negative, facultative
anaerobe, motile, oxidase-positive bacillus.1 It is widely
distributed in natural aquatic environments and is sensitive to
temperature.1e3 Usually it can produce an antioxidant pigment
called violacein associated with remarkable purple color.1 It
grows easily on nutrient agar (blood agar and MacConkey agar
media with incubation at 30 C to 45 C), producing distinctive
smooth low convex colonies with a dark violet metallic sheen* Corresponding author. Dr. Ching-Huei Yang, Division of Infectious
Diseases, Department of Internal Medicine Buddhist Tzu Chi General Hospital,
Taipei Branch, 289, Jianguo Rd., New Taipei City 231, Taiwan, ROC.
E-mail address: frankchy@tzuchi.com.tw (C.-H. Yang).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.08.013in the typical pigmented strain. Infection due to C. violaceum
is rare, so most clinicians are not familiar with it. However,
human infection, while rare, does occur. In this review, most of
the patients with this infection were healthy and young. Rapid
progress to sepsis with metastatic abscess (liver, lung, or
spleen) was the striking feature in C. violaceum infection.1,4,5
Also, it is noteworthy to emphasize the multidrug-resistant
characteristic of C. violaceum and the possibility of relapse.
In addition, this microorganism may not be confined to
a narrow geographic range (between latitudes 35N and 35S)
as previously considered because of the effect of global climate
change.1e3 This study reviews and analyzes the patients with
C. violaceum infection from the reported literature. The
primary objective was to emphasize the characteristics of the
difficult-to-treat in C. violaceum infection.hinese Medical Association. All rights reserved.
436 C.-H. Yang, Y.-H. Li / Journal of the Chinese Medical Association 74 (2011) 435e4412. Methods2.1. Study design and patientsAEnglish-language literature search from 1952 through 2009
was reviewed via the PubMed, Medline databases, and manual
searches. Foreign-language cases were included only if the
data provided were sufficient for evaluation.6e10 One case with
C. violaceum infection that occurred in Taiwan in September
2009 was enrolled in this study.11 Eleven cases cited by Johnson
and colleagues12 in 1971 and eighteen cases cited by Anah and
others13 in 2008were excluded because no relevant data could be
evaluated. Because of the published nature of this review,
patients withC. violaceum infectionmay be underestimated. The
published journals were reviewed and clinical information, if
available, including demographics, incubation period, predis-
posing factor, comorbidity, clinical presentation, laboratory and
microbiologic data, antimicrobial therapy, outcome, complica-
tion, and clinical course, were obtained for analysis.2.2. DefinitionThe referred year was defined as the time when patients were
infected; however, if the author did not mention the time when
patient was infected, the year referred to the time when the
journal was published. Sepsis was considered if patients ful-
filled the sepsis definition.14 Patients were considered to have
skin lesions if they had any of the following manifestations:
papular rashes, ulcer, nodular lesion, skin abscess, vesicles,
pustules, or lymphadenitis. Incubation period was defined as
definite exposure to the predisposing factors to disease onset.
Clinical course was defined as the interval from the onset of
symptoms to death or discharge from hospital. A patient was
considered to have exposure history if he/she had been exposed
to water or soil before the illness. Antimicrobial susceptibility
tests were obtained from the reviewed journals, if available. C.
violaceum with an intermediate result during a susceptibility
test was classified as resistant. Antimicrobial therapy was
considered appropriate if the treatment regimen included at
least one antimicrobial agent active against C. violaceum
in vitro. However, it was considered inappropriate if the drugs
did not have in vitro activity against the isolated strain or if the
patient did not receive antimicrobial therapy. Healthcare-
associated infection was defined as infection that occurred
more than 48 hours after hospital admission. Isolation of C.
violaceumwith the same susceptibilities obtained from different
clinical specimens in the same patient is defined as one isolate.
The year 1990 was used as a reference year because of generally
available of new antibacterial agents, including ciprofloxacin
(U.S. Food and Drug Administration [FDA] approval in 1987)
and imipenem/cilastatin (FDA approval in 1985).2.3. Statistical analysisFig. 1. Cases of C. violaceum infection reported in the world. Number above
each bar indicates the number of published cases with infection by each
decade.Two-sample t-tests were used to compare the differences in
continuous variables. Categorical data were compared using
Fisher’s exact test to resolve the concern of small sample sizesand sparse data. All statistical tests were analyzed with SPSS
Statistics 17.0 software (SPSS Inc., Chicago, IL, USA). A
p value of <0.05 was considered statistically significant.
3. Results3.1. Demographic data of the patientsWe studied 106 patients who presented with C. violaceum
infection between 1952 and 2009.1,4e10,12,13,15e36 More than
one-half of the patients (65%) were infected after 1990
(Fig. 1). Reported infections were far more common in the
northern hemisphere than in the southern hemisphere. Forty-
four (42%) of the 106 patients were reported in the region
of Americas, 43 (41%) in the East Western Pacific [including
10 in Australia, three in Vietnam, seven in Taiwan, one in
Japan, three in Korea, six in China (including Hong Kong),
seven in Malaysia, three in Singapore, one in Papua New
Guinean, one in Cambodia, and one in Laos], 16 in South East
Asia (including 10 in India, two in Sri Lanka, and four in
Thailand), and three in Africa (Fig. 2).3.2. Clinical characteristics and laboratory data of
patientsThe baseline demographic and medical characteristics of the
106 cases are listed in Table 1. Eighty percent of the infections
occurred in males. Most of the infected patients were young,
with a median age of 19.1 years old, ranging from 0 (newborn)
to 80 years old, 46 (42%) of whom were 10 years old. All of
the 106 patients were febrile. Incubation period from the
available 46 patients revealed a median duration of 3 days
(range, 1e90 days). Of the 106 patients, 33 (31.1%) had
experienced abdominal pain, emergency surgery was under-
taken in six (18.2%) during the clinical course, and localized
abscess was found in four.7,8,31 Seventy-two (68%) of the 106
patients had skin lesions during the clinical course, 87 (82%)
had sepsis at presentation, and 61 (58%) had C. violaceum as
Fig. 2. International distribution of patients with C. violaceum infection, indicating that C. violaceum infection occurs around the world. However, most of the cases
usually occur in tropical and subtropical regions.
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with an available hemogram, 46 (61%) had marked leukocy-
tosis with a median white blood cell (WBC) count of
20.9 109 cells/L (range, 12e61.9 109 cells/L); 12 (16%)
had marked leukopenia with a median WBC of 1.9 109 cells/
L (range, 0.09e3.3 109 cells/L); and 13 (17%) of the 106
patients had band form with a ratio of >10% in peripheral
WBC count. Sixteen (15%) of the 106 patients had comor-
bidities: nine had chronic granulomatous disease (CGD), two
had glucose-6-phosphatase deficiency, three had diabetes, one
had leukemia, and one had uremia. Localized abscesses were
found in 52 patients (49%). Among these patients, only the
liver was involved in 37 (35%); only the lung in 25 (24%); only
the spleen in 14 (13%); the liver plus the lung in 11 (10.4%);
and the liver plus the lung and spleen in 10 (9.4%). No specific
factor could be used to predict whether there was a metastatic
abscess or not in early C. violaceum infection. Nonpigmented
strains were found in 12 patients (11%).
Patients who had died had a shorter clinical course, with
a median duration of 7 days (range, 1e97 days), while the
survivors had a longer clinical course and a median duration of
18.5 days (range, 1e153 days). Fifty-three (50%) of the 106
patients received appropriate antimicrobial treatment. A
comparison of patients with C. violaceum infection with and
without bacteremia appears in Table 2. The group of patients
without bacteremia tended to be younger ( p¼ 0.007), had
a presence of sepsis ( p< 0.001), and a lower-case fatality rate
( p¼ 0.003).3.3. Potential predisposing factors associated with C.
violaceum infectionOf the 106 patients, 60 (57%) had potential factors predis-
posing them to invasive C. violaceum infection. These includedtrauma, exposure to water or soil, or both (Table 3). Fourteen
(23%) of the 60 patients with predisposing factors had both
histories of trauma and exposure. Of these patients, 35 (58%)
had history of specific exposure. Most of the young patients had
distinct predisposing factors, such as wading in water, playing in
muddy water, swimming, or falling in water, and these patients
tended to have a higher mortality rate. Of them, five patients fell
or played in muddy water; all five were children with a median
age of 2 years (range, 1.3e6 years), and they all subsequently
died. Nearly all of the patients had community-acquired infec-
tion; however, two patients may have had a healthcare-
associated infection. One patient, a man aged 64 years, had
persistent sepsis after cervical surgery.32 C. violaceum was
cultured from his blood and femoral line tip. He succumbed to
uncontrolled sepsis 3 months after cervical laminoplasty.
Another patient, a 16-year-old female, had received chemo-
therapy for acute leukemia,34 then developed pneumonia with
septic shock during hospitalization. Cultures from her blood and
Hickman catheter yielded nonpigmented C. violaceum.3.4. Microbiological data and antimicrobial
susceptibilitiesMost of the isolated strains were pigmented; however, there
were 12 (11%) isolated nonpigmented strains. Comorbidity
( p¼ 0.017) and localized abscess ( p¼ 0.029) were less
common in patients with nonpigmented strain infection. Disease
severity in these two groups showed no statistically significant
difference: sepsis ( p¼ 0.222), bacteremia ( p¼ 1.0), and death
( p¼ 0.063). Seventy-two isolated cases of C. violaceum from
various clinical specimens of 69 patients were studied for anti-
microbial susceptibility tests (Table 4). Piperacillin/tazobactam,
aminoglycosides, chloramphenicol, tetracycline, trimethoprim-
sulfamethoxazole, carbapenem, and fluoroquinolones exhibited
Table 1
Baseline demographic and medical characteristics of published C. violaceum
infection
Variable Patients (n¼ 106), no. (%)
Age (yr), mean SD, median (range) 20.1 19.1, 14.5 (<1e80)
Male sexa 84/105(80)
Incubation period, median days (range)b 3 (1e90)
Presence of skin lesion during
clinical course
72/106 (67.9)
Presence of predisposing factor (any) 60/106 (56.6)
Presence of abdominal pain
during clinical course
33/106 (31.1)
Sepsis at presentation 87/106 (82)
Bacteremia 61/106 (57.5)
White blood cell count, 109 cells/L
<12, no. (%) of patients, median (range) 46/75 (61.3), 20.9 (12e61.9)
4-12, no. (%) of patients, median (range) 17/75 (22.7), 9.07 (5.4e11.7)
>4, no. (%) of patients, median (range) 12/75 (16), 1.9 (0.09e3.3)
Band form >10%, no. (%) of patients,
median (range, %)
13/75 (17.3), 29 (10e62)
Comorbidity (any) 16/106 (15.1)
Chronic granulomatous disease 9/106 (8.5)
Glucose-6-phosphatase deficiency 2/106 (1.9)
Othersc 5/106 (4.7)
Localized abscess (any) 54/106 (50.9)
Liver 41/106 (38.7)
Lung 28/106 (26.4)
Spleen 13/106 (12.3)
Liverþ lung 11/106 (10.4)
Liverþ lungþ spleen 10/106 (9.4)
Other locationd 9
Year-specific case numbers
<1990 37/106 (34.9)
>1990 69/106 (65.1)
Appropriate antibiotic treatment 53/106 (50)
Relapse, no. (%), median
days of relapse (range)
7/106 (6.6), 135 (4e1095)
No. of patients with non-pigmented strain 13/106 (12.3)
Mortality 56 (53)
Clinical course, median days (range)e
Survivor 18.5 (1e153)
Death 7 (1e97)
a One neonate was excluded.
b Information on incubation period was available for 46 patients.
c Other comorbidities included three patients with diabetes, one with uremia,
and one with leukemia.
d Other locations of abscess included brain (three), breast (one), kidney
(one), intraabdomen (one), nasopharyngeal space (one), pericardium (one),
and psoas muscle (one).
e Information on clinical course was available for 95 patients.
Table 2
Comparison of patients with C. violaceum infection with and without
bacteremia
Characteristics Patients with
bacteremia
(n¼ 61)
Patients without
bacteremia
(n¼ 45)
p
Age (yr), mean SD
(range)
24.1 22.1
(<1e53)
14.8 12.4
(<1e80)
0.007
Male sex 47/60 (78.3) 37/45 (82.2) 0.806
Comorbidity (any) 7/61 (11.5) 8/45 (17.8) 0.406
Predisposing factor (any) 34/61 (55.7) 26/45 (57.8) 0.846
Skin lesion (any) 46/61 (75.4) 27/45 (60.0) 0.137
Sepsis 60/61 (98.4) 26/45 (57.8) <0.001
Localized abscess (any) 32/61 (52.5) 19/45 (42.2) 0.330
Year-specific case numbers
<1990 20/61 (32.8) 17/45 (37.8) 0.543
>1990 41/61 (67.2) 27/45 (60.0)
Appropriate antimicrobial
therapy
28/54 (51.9) 28/42 (66.7) 0.145
Death 40/61 (65.6) 16/45 (35.5) 0.003
Data are no. (%) patients, unless otherwise indicated.
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roquinolones exhibited the greatest susceptibility rate. Poly-
myxin B or colistin did not have a reliable susceptibility rate
given the limited data.3.5. Outcome and antimicrobial therapyFifty-six patients (53%) died of C. violaceum infection. Of
the 106 studied patients, 53 (50%) received appropriate anti-
microbial treatment. The most important risk factors inmortality for the 61 patients with C. violaceum bacteremia
were young age ( p¼ 0.0789), presence of localized abscess
( p¼ 0.030), shorter clinical course ( p< .001), and inappro-
priate antimicrobial treatment ( p< 0.001; Table 5). Forty-four
(94%) of the 47 survivors received appropriate antimicrobial
treatment. Among them, 34 (77%) received combination
therapy. Before 1990, chlorampenicol was the most common
antimicrobial agent for this infection; however, after 1990,
ciprofloxacin and carbapenem became the predominant anti-
microbial agents.3.6. RelapseSeven patients (6.6%) experienced relapse or reinfection,
with a median interval of 135 days (range, 4e1095 days). Of
the seven patients, four had two episodes of C. violaceum
infection: one was infected a second time 13 months after
completion of appropriate antimicrobial treatment, and one
died of a recurrent infection 2 weeks after adequate treat-
ment17,18; two patients who received inappropriate antimi-
crobial treatment had two episodes of infection, separated by 1
week and 2 weeks, respectively.23,26 One patient had an
infection relapse because of the inadequate duration of treat-
ment.4 Two patients experienced reinfection in two different
episodes: one had two episodes of infection, separated by 3
years after exposure to the same source,24 while another was
infected a second time 2 years after the first episode.22
4. Discussion
C. violaceum is widely distributed in natural aquatic envi-
ronments and is sensitive to temperature; therefore, it has
a predilection to the tropical and subtropical areas.1,2 It is
worth noting that the effects of global warming may increase,
and the geographic distribution of this microorganism may
change in the future. Several patients with C. violaceum
Table 3
Predisposing factors in patients with C. violaceum infection (n¼ 60)
Variable Patients no.(%) Age, median yr (range) Appropriate antimicrobial Therapy, no. (%) No. of deaths Mortality (%)
Trauma 9 (15) 24 (0.8e54) 6(67) 4 44
Exposure to water/soil 35(58) d 19 54
Near-drowning 5 (8) 39 (18e53) 3(60) 2 40
Swimming 12 (20) 10.5 (3e40) 8(67) 4 33
Wading in water 4 (7) 8.5 (6e24) 1(25) 2 50
Fall or play in muddy water 5 (8) 2 (1.3e6) 1(20) 5 100
Others 9 (15) 15 (4e44) 3(33) 6 67
Trauma and exposure to water/soil 14 (23) 31.5 (9e80) 5(39)a 8 57
Data are no. (%) of patients, unless otherwise indicated.
a The data for antimicrobial theapy were available for 13 patients.
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(confined between latitudes of 35N and 35S).1e3,26 At the
same time, reported cases of C. violaceum infection in the
literature surfaced in recent decades. Of the 106 patients, 69
(65%) were infected after 1990, which indicated that the
number of infections have substantially increased in recent
decades.Table 4
Antimicrobial susceptibilities in 72 isolates of C. violaceum
Antimicrobial agent No. tested No. (%) of
susceptible isolates
Penicillin 9 0
Ampicillin 39 1 (3)
Amoxicillin/clavulanate 9 0
Ampicillin/sulbactam 9 1 (11)
Carbenicillin 12 5 (42)
Ticarcillin 5 1 (20)
Piperacillin 15 10 (67)
Mezlocillin 3 1 (33)
Ticarcillin/clavulanate 9 5 (56)
Piperacillin/tazobactam 11 9 (82)
Cephalothin (or cephalexin/cefazolin) 39 0
Cefuroxime 16 0
Cefamandole 6 0
Ceftizoxime 7 0
Cefoxitin 9 1 (11)
Cefotaxime 21 6 (29)
Ceftriaxone 19 2 (11)
Ceftazidime 33 11 (33)
Cefepime 13 10 (77)
Aztreonam 12 9 (75)
Moxolactam 3 2 (67)
Carbapenema 34 31 (91)
Gentamicin 63 55 (87)
Netilmicin 11 11 (100)
Amikacin 35 27 (77)
Tobramycin 15 10 (67)
Kanamycin 5 4 (80)
Isepamicin 3 1 (33)
Ciprofloxacin 36 34 (94)
Levofloxacin 5 5 (100)
Ofloxacin 4 4 (100)
Pefloxacin 2 2 (100)
Chloramphenicol 42 41 (98)
Tetracycline 26 24 (92)
Trimethoprim/sulfamethoxazole 48 45 (94)
Polymyxin B (or colistin) 7 1 (14)
a Includes imipenem/cilastatin or meropenem.Human infection was first described in 1927.16 Less than
140 human cases (106 cases enrolled, but 29 cases were
excluded in this study) have been reported in the world. In
1988, Miller and colleagues37 conducted a study that
compared virulent and avirulent strains of C. violaceum, in
which virulent strains had elevated levels of superoxide dis-
mutase and catalase that may protect the microorganism fromTable 5
Demographic data, clinical characteristics, laboratory data, and treatment
associated with mortality in 61 patients with C. violaceum bacteremia
Variable No. of deaths/No. of cases Mortality (%) p
Sexa
Men 32/47 68 0.349
Women 7/13 54
Age, y
<6 13/20 65 0.0789
7e20 12/15 80
21e65 15/23 65
>65 0/3 0
Predisposing factor
Yes 23/33 70 0.462
No 17/28 61
Skin lesion
Yes 27/45 60 0.124
No 13/16 81
Abdominal pain
Yes 15/23 65 0.964
No 25/38 66
Comorbidity
Yes 14/19 74 0.561
No 26/42 62
Localized abscess (any)
Yes 26/33 79 0.030
No 14/28 50
Course, duration (d)b
<5 18/18 100 <0.001
6e20 14/16 88
>20 7/24 29
Appropriate antimicrobial treatment
Yes 5/24 21 <0.001
No 29/30 97
Values are reported as no./no. (%), unless otherwise indicated.
a Excluded one case of 8-day neonate.4
b Information on patient’s courses was available for 58 patients.
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virulence. Thus, it is possible that the place where patients
developed the infection may depend on the exact strain that
they contracted.
The distribution of the reported patients was quite different,
with 42% in the Americas and 39% in the East Western Pacific.
Approximately 42% of the patients were younger than 10 years.
Patients without a predisposing factor were nearly all children
(6 years of age [p¼ 0.061]). The scenario of “the more
outdoor activities, the more chance to be exposed to water or
soil and traumatic injury” may explain this phenomenon.
Of the 106 patients, 56 died, with an overall mortality rate
of 53%. Most of the patients had a short incubation time. The
most common symptoms of C. violaceum infections were
fever, pain over the infected site associated with various skin
lesions, abdominal pain, and rapid progression to sepsis.
Thirty-three (31.1%) patients experienced abdominal pain,
emergency surgery was performed in six (18.2%), and local-
ized visceral abscess was found in four patients. Seventy-two
(68%) patients had skin lesions with various manifestations, in
which pustules may have developed in the early period or
presented as a late manifestation preceding or accompanying
sepsis. Deposition of septic embolism in the small vessel was
the probable pathogenesis. Laboratory data were nonspecific
in C. violaceum infection; however, an abnormal hemogram
with leukocytosis, leukopenia, or left shift may occur (Table
1). Patients who died had a shorter clinical course compared
with the survivors. Seven patients (6.6%) experienced relapse.
It is possible that occult microabscess or hidden septic
focus may persist in a patient’s internal organs despite
adequate treatment. Therefore, it is necessary to treat patients
with C. violaceum infection for an extended period and
maintain close follow-up procedures. On the other hand,
healthcare-associated infection was considered in two cases in
this review.32,34 One study for neonatal sepsis conducted by
Anah and others in 2008 had demonstrated isolation of C.
violaceum from 10 inborn neonates (6.3%).14 These data
indicate that this microorganism might have existed in hospital
settings, and this warrants attention.
Rapid progression to life-threatening sepsis associated with
metastatic abscess in C. violaceum infection is the most
striking feature. Eighty-seven (82%) patients presented with
sepsis in the early manifestation of the infection (Table 1).
Localized abscess in visceral organs was found in nearly one-
half of the patients (52/106). It is worth noting that the
metastatic abscess could be the early clinical presentation of
the C. violaceum infection. The liver (35%) was the organ that
was most commonly involved. However, multiple visceral
abscesses may be present. Nonpigmented strains of C. viola-
ceum were found in 12 patients. Disease severity in these two
groups has not been shown to be statistically significant,
indicating that the pathogenicity of nonpigmented strains
seems to have similar virulence to that of pigmented strains.
This is consistent with the reported literature.37,38 Patients
with chronic granulomatous disease (CGD) have been
considered to be vulnerable to C. violaceum infection39;
however, there were only nine cases (8.5%) of proven CGD inthis survey. Sixty (57%) patients had potential factors that
predisposed them to invasive C. violaceum infection. Mosret
importantly, specific exposure, including near drowning,
swimming, wading in water, and falling or playing in muddy
water were risk for developing C. violaceum infection. It is
also worth noting that the clinical symptoms of C. violaceum
infection may not occur immediately after specific exposure to
water or soil; instead, they may occur 60 days after exposure.
The clinical spectrum of C. violaceum infection is protean,
including urinary tract infection, pneumonia, gastrointestinal
infection, localized cutaneous lesions, localized or metastatic
abscesses, osteomyelitis, meningitis, peritonitis, brain abscess,
endocarditis, hemophagocytic syndrome, respiratory distress
syndrome, and fulminant sepsis. Diagnosing C. violaceum
infection is currently based on a culture of clinical specimens
followed by subsequent biochemical identification. There is no
available examination for a serological test. In 2006, Scholz
and colleagues40 developed a method for detecting C. viola-
ceum by multiplex polymerase chain reaction, but it has not
been widely accepted to date.
Although antimicrobial susceptibility data on C. violaceum
remainvery limited because this pathogen is rarely isolated from
clinical specimens, results of susceptibility testing vary in
different clinical settings. The Clinical and Laboratory Stan-
dards Institute has not yet established a zone diameter for
resistance and susceptibility associated with minimum inhibi-
tory concentration (MIC) breakpoints. C. violaceum is found to
be extremely resistant to penicillins and cephalosporins (Table
4). Increased beta-lactamase activity in C. violacerum was re-
ported in one study by Farrar in 1976.41 In 1988 Aldridge and
others5 conducted another study to compare the in vitro activity
of ciprofloxacin and other antimicrobial agents against clinical
strains of C. violaceum. The effective agents of C. violaceum,
including ticarcillin, carbenicillin, and cefoxitin, which were
reported in 1976, no longer have acceptable susceptibility rates.5
Before 1990, the usual treatment for C. violaceum infection was
chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline,
or aminoglycosides. However, several new potent antimicro-
bials that were introduced after 1990, which include fluo-
roquinolone and carbapenem, have demonstrated good activity
against this microorganism. According to study by Aldridge,5
ciprofloxacin was the most active drug to combat C. violaceum.
Among the patients who survived, 44 (93.6%) received
appropriate antimicrobial treatment. Among these patients, 34
(77.3%) had received combination therapy with a regimen of
chloramphenicol, beta-lactams, trimethoprim-sulfamethox-
azole, or fluoroquinolones along with one of the aminoglyco-
sides. As shown in Table 4, most of the beta-lactams do not
exhibit good activity with respect to C. violaceum. An extensive
treatment period of parenteral antimicrobials for 2e4 weeks for
C. violaceum infection, followed by maintenance therapy with
an oral agent, such as trimethoprim-sulfamethoxazole, tetra-
cycline, or fluoroquinolone, for 2e3 months to prevent relapse
is recommended.4,15,21,30 Only 50% of the patients received
appropriate antimicrobial treatment (Table 1), and appropriate
antimicrobial treatment was the significant risk factor for
mortality in patients with C. violaceum bacteremia ( p< 0.001;
441C.-H. Yang, Y.-H. Li / Journal of the Chinese Medical Association 74 (2011) 435e441Table 5). Therefore, it is important for physicians to be aware of
C. violaceum infection and its appropriate antimicrobial treat-
ment regimen.
In conclusion, C. violaceum infection may become an
emergent infection after further global climate change. It
represents a difficult-to-treat entity, so special attention is
required. A prompt diagnosis, optimal antimicrobial therapy,
and adequate therapeutic duration for C. violaceum infection
are the keys for successful therapy.References
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